IDeA States Pediatric Clinical Trials Network for Underserved and Rural Communities

Robert D Annett1, Sheva Chervinskiy2, Thomas H Chun3

  • 1Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi; rannett@umc.edu.

Pediatrics
|September 18, 2020
PubMed

Insights

The ECHO Institutional Development Awards States Pediatric Clinical Trials Network (ISPCTN) enhances pediatric clinical trials in underserved areas. It builds research infrastructure and trains scientists to improve children's health outcomes.

Area of Science:

  • Pediatric Health Research
  • Clinical Trials Network Development
  • Environmental Health Studies

Background:

  • The National Institutes of Health's Environmental Influences on Child Health Outcomes (ECHO) program addresses high-priority pediatric conditions.
  • The ECHO program includes established pediatric cohorts and the ECHO Institutional Development Awards States Pediatric Clinical Trials Network (ISPCTN).

Purpose of the Study:

  • To provide an overview of the ISPCTN.
  • To highlight the ISPCTN's role in enhancing clinical trials capabilities for pediatrician scientists.
  • To emphasize the network's commitment to conducting trials in underserved and rural communities.

Main Methods:

  • The ISPCTN focuses on building research infrastructure at network sites.
  • Training is provided to pediatric faculty and coordinators.
  • Community and family engagement strategies are implemented.

Main Results:

  • The ISPCTN has made significant progress in professional development and regulatory procedures.
  • Two large research studies were initiated within the first 18 months.
  • Findings indicate successful progress toward network sustainability.

Conclusions:

  • The ISPCTN is crucial for expanding pediatric clinical trial infrastructure and expertise.
  • The network effectively supports state-of-the-science trials for children in underserved areas.
  • ISPCTN's approach enhances research capacity and contributes to improving child health outcomes.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
166
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
145
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108